High-Power Thulium Laser Vaporization of the Prostate: Short-Term Outcomes of Safety and Effectiveness
- 1 November 2014
- journal article
- Published by SAGE Publications in Journal of Endourology
- Vol. 28 (11) , 1357-1362
Abstract
The thulium laser was introduced in 2005 for the treatment of benign prostatic hyperplasia (BPH). Enucleation studies from outside North America show comparable efficacy and lower morbidity to transurethral resection of the prostate. A few studies exist describing outcomes of vaporization, the most commonly used technique for urologists. We present our 3-month outcomes of thulium laser vaporization of the prostate (ThuVP). From December 2010 to October 2013, 68 men underwent ThuVP using the 150 W CyberTM(®). Data were collected on demographics, comorbidities, intraoperative measures, complications, serum parameters, maximum flow rate (Qmax), postvoid residual (PVR), International Prostate Symptom Score (IPSS), quality-of-life (QoL) score, and prostate-specific antigen. Patients were evaluated at 1 week, 1 month, and 3 months postoperatively. Nine patients were excluded for known prostate cancer. The mean age was 66±10 years, with a mean prostate size of 57±30 mL. At baseline, the mean IPSS was 19.9±8.0, QoL score was 4.5±1.1, Qmax was 5.2±4.5 mL/sec, and PVR was 220±397 mL. The mean laser time was 35±18 minutes, and energy used was 234±139 kJ. Forty-seven (78%) patients were discharged the day of surgery. No blood transfusions were administered with a mean drop in hemoglobin of 0.7±0.8 g/dL (p<0.05). There were no Clavien grade≥III complications within 30 days of surgery. Six (10%) patients were diagnosed with urinary tract infection. Significant improvements from baseline were seen in Qmax, PVR, IPSS, and QoL score. All 15 patients who were in retention were voiding at the last follow-up. Thulium laser vaporization of the prostate appears to be a safe and effective outpatient technique for the treatment of BPH with durable outcomes at 3 months.Keywords
This publication has 32 references indexed in Scilit:
- Morbidity and Mortality After Benign Prostatic Hyperplasia Surgery: Data from the American College of Surgeons National Surgical Quality Improvement ProgramJournal of Endourology, 2014
- Thulium laser vaporesection versus standard transurethral resection of the prostate: A randomized trial with transpulmonary thermodilution hemodynamic monitoringInternational Journal of Urology, 2012
- Outcomes and Complications After 532 nm Laser Prostatectomy in Anticoagulated Patients With Benign Prostatic HyperplasiaJournal of Urology, 2011
- Comparison of 2-μm Continuous Wave Laser Vaporesection of the Prostate and Transurethral Resection of the Prostate: A Prospective Nonrandomized Trial With 1-year Follow-upUrology, 2010
- Practice Patterns in Benign Prostatic Hyperplasia Surgical Therapy: The Dramatic Increase in Minimally Invasive TechnologiesJournal of Urology, 2008
- Thulium Laser versus Standard Transurethral Resection of the Prostate: A Randomized Prospective TrialEuropean Urology, 2008
- Complications of Transurethral Resection of the Prostate (TURP)—Incidence, Management, and PreventionEuropean Urology, 2006
- High-Power Thulium Fiber Laser Ablation of Urinary Tissues at 1.94 µmJournal of Endourology, 2005
- Incidence and Prevalence of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Primary Care—The Triumph ProjectEuropean Urology, 2002
- Transurethral Prostatectomy: Immediate and Postoperative Complications. A Cooperative Study of 13 Participating Institutions Evaluating 3,885 PatientsJournal of Urology, 1989